ROKIT Healthcare said on the 8th that it has swiftly hired global bio expert Dr. Lee Nadan as chief technology officer (CTO).
The company plans to use this appointment to accelerate entry into the U.S. market for its core kidney and cartilage regeneration platforms and to expand its global business.
After receiving a doctorate from Johns Hopkins University in the United States, CTO Lee Nadan worked as a postdoctoral researcher at the National Institutes of Health (NIH) and Harvard Medical School. Lee then led research and development at world-class institutions including the Broad Institute, a joint research institute of Harvard University and the Massachusetts Institute of Technology (MIT), and Mass General Brigham, and published research results in international journals "Cell" and "Nature Cell Biology."
Lee has experience not only in research but also in commercialization. Lee headed management at a nanotechnology corporation founded by researchers from Harvard and MIT and led business growth, and handled partnership strategy with global pharmaceutical companies at an AI-based gene and cell therapy corporation.
Lee also participated in drafting the technology roadmap for the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and, while working as a venture investment partner, built the U.S. bio ecosystem and investment network.
ROKIT Healthcare plans to use Lee's addition to ramp up U.S. clinical development and commercialization of the kidney regeneration and cartilage regeneration areas within its AI-based organ regeneration platform. It also expects to expand technology exports and strategic alliances with global pharmaceutical companies.
CTO Lee Nadan said, "ROKIT Healthcare has a competitive platform that combines AI with patient-specific regenerative medicine technology," and added, "We will organically link scientific validation, clinical development, and commercialization strategy to lead the global market entry of the kidney and cartilage regeneration pipelines."